Methylation
Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism
09/10/2008
DNA methylation of CpG dinucleotides is an important
epigenetic modification of mammalian genomes and is
essential for the regulation of chromatin structure,
of gene expression and of genome stability1, 2.
Differences in DNA methylation patterns underlie a
wide range of biological processes, such as genomic
imprinting, inactivation of the X chromosome,
embryogenesis, and carcinogenesis3, 4, 5, 6.
Inheritance of the epigenetic methylation pattern is
mediated by the enzyme DNA methyltransferase 1
(Dnmt1), which methylates newly synthesized CpG
sequences during DNA replication, depending on the
methylation status of the template strands7, 8. The
protein UHRF1 (also known as Np95 and ICBP90)
recognizes hemi-methylation sites via a SET and
RING-associated (SRA) domain and directs Dnmt1 to
these sites9, 10, 11. Here we report the crystal
structures of the SRA domain in free and
hemi-methylated DNA-bound states. The SRA domain
folds into a globular structure with a basic concave
surface formed by highly conserved residues. Binding
of DNA to the concave surface causes a loop and an
amino-terminal tail of the SRA domain to fold into
DNA interfaces at the major and minor grooves of the
methylation site. In contrast to fully methylated CpG
sites recognized by the methyl-CpG-binding domain12,
13, the methylcytosine base at the hemi-methylated
site is flipped out of the DNA helix in the SRA–DNA
complex and fits tightly into a protein pocket on the
concave surface. The complex structure suggests that
the successive flip out of the pre-existing
methylated cytosine and the target cytosine to be
methylated is associated with the coordinated
transfer of the hemi-methylated CpG site from UHRF1
to Dnmt1.
Nature 455, 818-821 (9 October 2008) | doi:10.1038/nature07249
Nature 455, 818-821 (9 October 2008) | doi:10.1038/nature07249
|
Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1
09/10/2008
Epigenetic inheritance in mammals is characterized by
high-fidelity replication of CpG methylation patterns
during development1, 2. UHRF1 (also known as ICBP90
in humans and Np95 in mouse)3 is an E3 ligase
important for the maintenance of global and local DNA
methylation in vivo 4, 5. The preferential affinity
of UHRF1 for hemi-methylated DNA over symmetrically
methylated DNA by means of its SET and
RING-associated (SRA) domain6 and its association
with the maintenance DNA methyltransferase 1 (DNMT1)
suggests a role in replication of the epigenetic
code4, 5, 7. Here we report the 1.7 Å crystal
structure of the apo SRA domain of human UHRF1 and a
2.2 Å structure of its complex with hemi-methylated
DNA, revealing a previously unknown reading mechanism
for methylated CpG sites (mCpG). The SRA–DNA complex
has several notable structural features including a
binding pocket that accommodates the 5-methylcytosine
that is flipped out of the duplex DNA. Two
specialized loops reach through the resulting gap in
the DNA from both the major and the minor grooves to
read the other three bases of the CpG duplex. The
major groove loop confers both specificity for the
CpG dinucleotide and discrimination against
methylation of deoxycytidine of the complementary
strand. The structure, along with mutagenesis data,
suggests how UHRF1 acts as a key factor for DNMT1
maintenance methylation through recognition of a
fundamental unit of epigenetic inheritance, mCpG.
Nature 455, 822-825 (9 October 2008) | doi:10.1038/nature07273
Nature 455, 822-825 (9 October 2008) | doi:10.1038/nature07273
A piRNA Pathway Primed by Individual Transposons Is Linked to De Novo DNA Methylation in Mice
26/09/2008
piRNAs and Piwi proteins have been implicated in
transposon control and are linked to transposon
methylation in mammals. Here we examined the
construction of the piRNA system in the restricted
developmental window in which methylation patterns
are set during mammalian embryogenesis. We find
robust expression of two Piwi family proteins, MIWI2
and MILI. Their associated piRNA profiles reveal
differences from Drosophila wherein large piRNA
clusters act as master regulators of silencing.
Instead, in mammals, dispersed transposon copies
initiate the pathway, producing primary piRNAs, which
predominantly join MILI in the cytoplasm. MIWI2,
whose nuclear localization and association with
piRNAs depend upon MILI, is enriched for secondary
piRNAs antisense to the elements that it controls.
The Piwi pathway lies upstream of known mediators of
DNA methylation, since piRNAs are still produced in
dnmt3L mutants, which fail to methylate transposons.
This implicates piRNAs as specificity determinants of
DNA methylation in germ cells.
Molecular Cell, Vol 31, 785-799, 26 September 2008
Molecular Cell, Vol 31, 785-799, 26 September 2008
An Sp1/Sp3 Binding Polymorphism Confers Methylation Protection
28/08/2008
The factors that guide DNA hypermethylation in cancer
are poorly understood. We identified the candidate
tumor-suppressor gene, RIL, as a frequent methylation
target in cancer. Here, we report on a 12-bp
polymorphic sequence around its transcription start
site that creates a long allele. Methylation analysis
showed that, in aging colon, colon cancer, and
leukemias, the short allele had 2.1–3.1-fold higher
methylation than the long allele (P<0.001). Short
and long alleles had similar expression levels in
EBV-transformed cell lines. Electrophorectic mobility
shift assay showed that the inserted region of the
long allele binds Sp1 and Sp3 transcription factors.
Transfection of RIL allele-specific transgenes showed
no effects of the additional Sp1 site on
transcription early on, but methylation-seeded
constructs showed gradually decreasing transcription
from the short allele with eventual spreading of de
novo methylation. By contrast, the long allele showed
stable expression over time as measured by
luciferase, and ~2–3-fold lower levels of methylation
by bisulfite sequencing (P<0.001), suggesting that
the polymorphic Sp1 site protects against
time-dependent silencing. Our finding demonstrates
that in some genes, hypermethylation in cancer is
dictated by protein-DNA interactions at the promoters
and provides a novel mechanism by which genetic
polymorphisms can influence an epigenetic state.
PLoS Genet 4(8): e1000162. doi:10.1371/journal.pgen.1000162
PLoS Genet 4(8): e1000162. doi:10.1371/journal.pgen.1000162
Genome-scale DNA methylation maps of pluripotent and differentiated cells
07/08/2008
DNA methylation is essential for normal development1,
2, 3 and has been implicated in many pathologies
including cancer4, 5. Our knowledge about the
genome-wide distribution of DNA methylation, how it
changes during cellular differentiation and how it
relates to histone methylation and other chromatin
modifications in mammals remains limited. Here we
report the generation and analysis of genome-scale
DNA methylation profiles at nucleotide resolution in
mammalian cells. Using high-throughput reduced
representation bisulphite sequencing6 and
single-molecule-based sequencing, we generated DNA
methylation maps covering most CpG islands, and a
representative sampling of conserved non-coding
elements, transposons and other genomic features, for
mouse embryonic stem cells,
embryonic-stem-cell-derived and primary neural cells,
and eight other primary tissues. Several key findings
emerge from the data. First, DNA methylation patterns
are better correlated with histone methylation
patterns than with the underlying genome sequence
context. Second, methylation of CpGs are dynamic
epigenetic marks that undergo extensive changes
during cellular differentiation, particularly in
regulatory regions outside of core promoters. Third,
analysis of embryonic-stem-cell-derived and primary
cells reveals that 'weak' CpG islands associated with
a specific set of developmentally regulated genes
undergo aberrant hypermethylation during extended
proliferation in vitro, in a pattern reminiscent of
that reported in some primary tumours. More
generally, the results establish reduced
representation bisulphite sequencing as a powerful
technology for epigenetic profiling of cell
populations relevant to developmental biology, cancer
and regenerative medicine.
Nature 454, 766-770 (7 August 2008) | doi:10.1038/nature07107; Received 24 March 2008; Accepted 21 May 2008; Published online 6 July 2008
Nature 454, 766-770 (7 August 2008) | doi:10.1038/nature07107; Received 24 March 2008; Accepted 21 May 2008; Published online 6 July 2008
Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development
07/08/2007
The hypothesis of fetal origins of adult disease
posits that early developmental exposures involve
epigenetic modifications, such as DNA methylation,
that influence adult disease susceptibility. In utero
or neonatal exposure to bisphenol A (BPA), a
high-production-volume chemical used in the
manufacture of polycarbonate plastic, is associated
with higher body weight, increased breast and
prostate cancer, and altered reproductive function.
This study shows that maternal exposure to this
endocrine-active compound shifted the coat color
distribution of viable yellow agouti (A vy) mouse
offspring toward yellow by decreasing CpG
(cytosine-guanine dinucleotide) methylation in an
intracisternal A particle retrotransposon upstream of
the Agouti gene. CpG methylation also was decreased
at another metastable locus, the CDK5
activator-binding protein (Cabp IAP). DNA methylation
at the A vy locus was similar in tissues from the
three germ layers, providing evidence that epigenetic
patterning during early stem cell development is
sensitive to BPA exposure. Moreover, maternal dietary
supplementation, with either methyl donors like folic
acid or the phytoestrogen genistein, negated the DNA
hypomethylating effect of BPA. Thus, we present
compelling evidence that early developmental exposure
to BPA can change offspring phenotype by stably
altering the epigenome, an effect that can be
counteracted by maternal dietary supplements.
PNAS August 7, 2007 vol. 104 no. 32 13056-13061
PNAS August 7, 2007 vol. 104 no. 32 13056-13061

